{
    "id": 28824,
    "fullName": "PTPN11 P491Q",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "PTPN11 P491Q lies within the tyrosine-protein phosphatase domain of the Ptpn11 protein (UniProt.org). P491Q has been demonstrated to confer resistance to SHP2 inhibitors in culture (PMID: 30045908), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Nov 2019).",
            "references": [
                {
                    "id": 12547,
                    "pubMedId": 30045908,
                    "title": "SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045908"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5781,
        "geneSymbol": "PTPN11",
        "terms": [
            "PTPN11",
            "BPTP3",
            "CFC",
            "JMML",
            "METCDS",
            "NS1",
            "PTP-1D",
            "PTP2C",
            "SH-PTP2",
            "SH-PTP3",
            "SHP2"
        ]
    },
    "variant": "P491Q",
    "createDate": "10/10/2018",
    "updateDate": "11/03/2019",
    "referenceTranscriptCoordinates": {
        "id": 177547,
        "transcript": "NM_002834",
        "gDna": "chr12:g.112489048_112489049delCCinsAA",
        "cDna": "c.1472_1473delCCinsAA",
        "protein": "p.P491Q",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 15053,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, pancreatic ductal adenocarcinoma cells harboring KRAS G12C and expressing PTPN11 P491Q were resistant to the combination therapy, Selumetinib (AZD6244) and SHP099, in culture (PMID: 30045908).",
            "molecularProfile": {
                "id": 30712,
                "profileName": "KRAS G12C PTPN11 P491Q"
            },
            "therapy": {
                "id": 7400,
                "therapyName": "Selumetinib + SHP099",
                "synonyms": null
            },
            "indication": {
                "id": 3498,
                "name": "pancreatic ductal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 12547,
                    "pubMedId": 30045908,
                    "title": "SHP2 Inhibition Prevents Adaptive Resistance to MEK Inhibitors in Multiple Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045908"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 30708,
            "profileName": "PTPN11 P491Q",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30712,
            "profileName": "KRAS G12C PTPN11 P491Q",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 177547,
            "transcript": "NM_002834",
            "gDna": "chr12:g.112489048_112489049delCCinsAA",
            "cDna": "c.1472_1473delCCinsAA",
            "protein": "p.P491Q",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}